Potential concerns about generic substitution: Bioequivalence versus therapeutic equivalence of different amlodipine salt forms

Current Medical Research and Opinion

Volumn 25, Issue 9, 2009, Pages 2179-2189

  Meredith, Peter A ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Amlodipine; Biological availability; Cardiovascular agents; Drug toxicity; Generic drugs; Therapeutic equivalency

Indexed keywords

ACETYLSALICYLIC ACID; ALPRENOLOL; AMLODEPINE MALEATE; AMLODIPINE; AMLODIPINE BESYLATE; ANTICONVULSIVE AGENT; DEXTROPROPOXYPHENE; DIGOXIN; GENERIC DRUG; IMMUNOSUPPRESSIVE AGENT; PLACEBO; PRAVADOLINE; PROCAINAMIDE; UNCLASSIFIED DRUG; VERAPAMIL; WARFARIN;

ANGINA PECTORIS; ANTIHYPERTENSIVE ACTIVITY; BIOEQUIVALENCE; BIOLOGICAL ACTIVITY; CLINICAL TRIAL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG IMPURITY; DRUG MANUFACTURE; DRUG SAFETY; DRUG STABILITY; DRUG TOLERABILITY; HUMAN; HYPERTENSION; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PATIENT SAFETY; REVIEW; TREATMENT DURATION; VALIDITY;

AMLODIPINE; ANTIHYPERTENSIVE AGENTS; DISSENT AND DISPUTES; DOSAGE FORMS; DRUG COMPOUNDING; DRUGS, GENERIC; HUMANS; HYPERTENSION; SALTS; THERAPEUTIC EQUIVALENCY; WITHHOLDING TREATMENT;

EID: 69849098705     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990903116867     Document Type: Review

References (59)

1. Genazzani AA, Pattarino F. Difficulties in the production of identical drug products from a pharmaceutical technology viewpoint. Drugs R D 2008;9:65-72 (Pubitemid 351311220)
2. World Health Organization. Available at: http://www.who.int/trade/ glossary/story034/en/index.html
3. U.S. Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER), Orange Book - Approved drug products with therapeutic equivalence evaluations, 28th edn, 2008. Available at: http://www.fda.gov/cder/ orange/obannual.pdf
4. European Medicines Agency (EMEA), Committee for Proprietary Medicinal Products (CPMP), Note for guidance on the investigation of bioavailability and bioequivalence, CPMP/EWP/QWP/1401/98, July 2001
5. U.S. Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER), Guidance for industry: Bioavailability and bioequivalence studies for orally administered drug products - general considerations, March 2003
6. Meredith PA, The Unique Adalat Story - Nifedipine Gastrointestinal Therapeutic System. European Cardiovascular Disease 2007; Issue 1, July 2007. Available at: http://www.touchbriefings.com/cdps/cditem.cfm?nid=2744&cid= 5#Hypertension
7. Verbeeck RK, Kanfer I, Walker RB. Generic substitution: the use of medicinal products containing different salts and implications for safety and efficacy. Eur J Pharm Sci 2006;28:1-6
8. Basak AK, Raw AS, Al Hakim AH, et al. Pharmaceutical impurities: regulatory perspective for Abbreviated New Drug Applications. Adv Drug Deliv Rev 2007;59:64-72
9. Chen ML, Shah V, Patnaik R, et al. Bioavailability and bioequivalence: an FDA regulatory overview. Pharm Res 2001;18:1645-1650 (Pubitemid 34020417)
10. Nakai K, Fujita M, Ogata H. International harmonization of bioequivalence studies and issues shared in common. Yakugaku Zasshi 2000;120:1193-1200
11. Meredith P. Bioequivalence and other unresolved issues in generic drug substitution. Clin Ther 2003;25:2875-2890 (Pubitemid 37510596)
12. Birkett DJ. Generics - equal or not? Austr Prescr 2003;26:85-87
13. Besag FM. Is generic prescribing acceptable in epilepsy? Drug Saf 2000;23:173-182
14. European Medicines Agency (EMEA), CPMP Efficacy Working Party Therapeutic Subgroup on Pharmacokinetics (EWP-PK), July 2006. Available at: http://www.emea.europa.eu/pdfs/human/ewp/4032606en.pdf
15. Midha KK, Rawson MJ, Hubbard JW. The bioequivalence of highly variable drugs and drug products. Int J Clin Pharmacol Ther 2005;43:485-498
16. U.S. Food and Drug Administration (FDA), Therapeutic equivalence of generic drugs: Letter to health practitioners, January 1998. Available at: http://www.fda.gov/cder/news/nightgenlett.htm
17. Mignini F, Tomassoni D, Traini E, et al. Single-dose, randomized, crossover bioequivalence study of amlodipine maleate versus amlodipine besylate in healthy volunteers. Clin Exp Hypertens 2007;29:539-552 (Pubitemid 350223248)
18. Donnelly R, Meredith PA, Miller SH, et al. Pharmacodynamic modeling of the antihypertensive response to amlodipine. Clin Pharmacol Ther 1993;54:303-310 (Pubitemid 23294531)
19. Meredith PA. Generic drugs. Therapeutic equivalence. Drug Saf 1996;15:233-242
20. Carter BL, Noyes MA, Demmler RW. Differences in serum concentrations of and responses to generic verapamil in the elderly. Pharmacotherapy 1993;13:359-368
21. Borgherini G. The bioequivalence and therapeutic efficacy of generic versus brand-name psychoactive drugs. Clin Ther 2003;25:1578-1592 (Pubitemid 36801937)
22. Nakai K, Fujita M, Ogata H. New bioequivalence studies: individual bioequivalence and population bioequivalence. Yakugaku Zasshi 2000;120:1201-1208
23. Chen ML, Lesko LJ. Individual bioequivalence revisited. Clin Pharmacokinet 2001;40:701-706
24. Laroche ML, Merle L. Generic and brand-name drugs. Are different criteria sufficiently taken into account before granting market authorisation? Acta Clin Belg Suppl 2006;(1):48-50
25. Furberg BD, Furberg CD. Are all drugs of a class interchangeable? In: Evaluating Clinical Research: All that Glitters is not Gold. New York: Springer, 2007:115-119
26. Wiecek A, Mikhail A. European regulatory guidelines for biosimilars. Nephrol Dial Transplant 2006;21(Suppl 5):v17-20
27. Davies G. Changing the salt, changing the drug. Pharm J 2001;266:322-323
28. Frank RG. The ongoing regulation of generic drugs. N Engl J Med 2007;357:1993-1996
29. Snider DA, Addicks W, Owens W. Polymorphism in generic drug product development. Adv Drug Deliv Rev 2004;56:391-395 (Pubitemid 38201431)
30. Everett RM, Descotes G, Rollin M, et al. Nephrotoxicity of pravadoline maleate (WIN 48098-6) in dogs: evidence of maleic acid-induced acute tubular necrosis. Fundam Appl Toxicol 1993;21:59-65 (Pubitemid 23225985)
31. Olovson SG, Havu N, Regårdh CG, et al. Oesophageal ulcerations and plasma levels of different alprenolol salts: potential implications for the clinic. Acta Pharmacol Toxicol (Copenh) 1986;58:55-60 (Pubitemid 16212800)
32. U.S. Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER), Guidance for industry: Q3A impurities in new drug substances, June 2008
33. U.S. Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER), Guidance for industry: Q3B(R2) impurities in new drug products, July 2006
34. Amlodipine Citizen Petition by Pfizer Inc. Available at: http://www.fda.gov/ohrms/dockets/dailys/03/Sept03/090303/03p-0408-cp00001-08- Tab-G-vol3.pdf
35. Sudhakar P, Nirmala M, Moses Babu J, et al. Identification and characterization of potential impurities of amlodipine maleate. J Pharm Biomed Anal 2006;40:605-613 (Pubitemid 43227384)
36. Murakami T, Fukutsu N, Kondo J, et al. Application of liquid chromatography-two-dimensional nuclear magnetic resonance spectroscopy using pre-concentration column trapping and liquid chromatography-mass spectrometry for the identification of degradation products in stressed commercial amlodipine maleate tablets. J Chromatogr A 2008;1181:67-76
37. European Medicines Agency (EMEA), Committee for Medicinal Products for Human Use (CHMP), Guideline on the limits of genotoxic impurities, EMEA/CHMP/QWP/251344/2006, London 2006
38. Murdoch D, Heel RC. Amlodipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiovascular disease. Drugs 1991;41:478-505
39. Norvasc®. Pfizer Inc. Available at: http://www.fda.gov/cder/foi/ label/2007/019787s042lbl.pdf
40. Clavijo GA, de Clavijo IV, Weart CW. Amlodipine: a new calcium antagonist. Am J Hosp Pharm 1994;51:59-68
41. Istin®. Pfizer Inc. Available at: http://emc.medicines.org.uk/emc/ assets/c/html/displaydoc.asp?documentid=1466
42. Amlor®. Pfizer Inc. Available at: http://www.pfizer.fr/Portals/0/ AMLOR%20Notice%20commune%205%20et%2010mg%20INT.pdf
43. Wang JG, Li Y, Franklin SS, et al. Prevention of stroke and myocardial infarction by amlodipine and angiotensin receptor blockers: a quantitative overview. Hypertension 2007;50:181-188 (Pubitemid 46986040)
44. Data on file. Pfizer Inc
45. European Medicines Agency (EMEA), Committee for Proprietary Medicinal Products (CPMP), Opinion following an article 29 referral: Amlovita. London 26 April 2004. EMEA/CPMP/539/04
46. European Medicines Agency (EMEA), Committee for Proprietary Medicinal Products (CPMP), Opinion following an article 29 referral: Talam. London 27 April 2004. EMEA/CPMP/540/04
47. Park S, Chung N, Kwon J, et al. Results of a multicenter, 8-week, parallel-group, randomized, double-blind, double-dummy, phase III clinical trial to evaluate the efficacy and tolerability of amlodipine maleate versus amlodipine besylate in Korean patients with mild to moderate hypertension. Clin Ther 2005;27:441-450 (Pubitemid 40732651)
48. New amlodipine (Amloc®) product available in South Africa. Cardiovasc J S Afr 2005;16:61
49. Pragai G, Orosz E, Szilagyi J, et al. United States Patent Application Publication, US 2005/0019395 A1, January 27, 2005
50. Harrison HE, Harrison HC. Experimental production of renal glycosuria, phosphaturia, and aminoaciduria by injection of maleic acid. Science 1954;120:606-608
51. Angielsky S, Rogulski J. Aminoaciduria caused by maleic acid. III. The effect of sulfhydryl compounds. Acta Biochim Pol 1959;6:411-415
52. Zager RA, Johnson AC, Naito M, et al. Maleate nephrotoxicity: mechanisms of injury and correlates with ischemic/hypoxic tubular cell death. Am J Physiol Renal Physiol 2008;294:F187-97
53. Makowiecka-Cieśla M, Januszewicz A, Prejbisz A, et al. Nine month follow-up of amlodipine maleate and amlodipine besylate treatment in patients with essential hypertension: does the salt form matter? Arterial Hypertension 2005;9:364-373
54. Elliott HL, Meredith PA, Reid JL, et al A comparison of the disposition of single oral doses of amlodipine in young and elderly subjects. J Cardiovasc Pharmacol 1988;12(Suppl 7):S64-6
55. Abernethy DR, Gutkowska J, Winterbottom LM. Effects of amlodipine, a long-acting dihydropyridine calcium antagonist in aging hypertension: pharmacodynamics in relation to disposition. Clin Pharmacol Ther 1990;48:76-86 (Pubitemid 20236205)
56. Verdecchia P, Reboldi G, Angeli F, et al. Angiotensin-converting enzyme inhibitors and calcium channel blockers for coronary heart disease and stroke prevention. Hypertension. 2005;46:386-392 (Pubitemid 41099174)
57. Wald DS, Law M, Morris JK, et al. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med 2009;122:290-300
58. Neaton JD, Grimm Jr RH, Prineas RJ, et al. Treatment of Mild Hypertension Study. Final results. JAMA 1993;270:713-724
59. U.S. Food and Drug Administration (FDA), Department of Health and Human Services, Food and Drug Administration Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER): Guidance for Industry: Population Pharmacokinetics, February 1999. Available at: http://www.fda.gov/CDER/guidance/1852fnl.pdf